The adipocyte-derived hormone, leptin, which plays a principal role in regulating feeding behavior and energy expenditure, modulates central dopamine systems at multiple levels. [1] [2] [3] In ob/ob mice, which have a genetic mutation that renders them leptindeficient, leptin administration was shown to increase dopamine D 2 /D 3 receptor availability in the nucleus accumbens (NAC) by 21% and in the caudate putamen by 29%. 2 We now show that in congenitally leptin-deficient humans with an analogous mutation, resumption of leptin treatment, after long-term replacement and short-term removal, does not significantly increase striatal D 2 /D 3 receptor availability.
Three leptin-deficient patients (32-year-old male A, 39-and 44-year-old females B and C, respectively) from a family in Turkey and 16 age-and sex-matched healthy control subjects (6 men, 10 women: mean age = 35.3, s.d. = 8.7) were tested. Patients have a rare, recessive, missense mutation in the ob gene. They had been treated daily with recombinant methionyl human leptin replacement (r-metHuLeptin; Amylin Pharmaceuticals, San Diego, CA, USA) for 6 years at the time of this study. As described previously, the treatment substantially normalized eating behavior, weight and endocrine function, reversibly increased cerebral gray matter concentration, and altered the brain response to food-related cues. ), a radiotracer with high affinity for these receptors. Each participant underwent two [
18 F]fallypride-scanning sessions. The first session was conducted after daily leptin supplementation had been discontinued for 30-32 days ('off-leptin' condition). The second session was conducted 12-15 days after supplementation resumed ('on-leptin' condition). Control group sessions were separated by 21-75 days, without leptin administration.
The positron emission tomography procedure and definition of volumes of interest were described previously.
10 D 2 /D 3 receptor binding was estimated in the NAC, globus pallidus, putamen and caudate nucleus. Volumes of interest were placed using the ''FIRST'' subcortical segmentation routines within the FSL software distribution (http://www.fmrib.ox.ac. uk/fsl/first/index.html) (Figure 1a ). Binding potential (BPND), which represents D 2 /D 3 receptor availability, was determined as described previously, 10 using the simplified reference tissue model with the cerebellum, which is relatively devoid of D 2 /D 3 receptors, as a reference region.
We computed differences scores (session 2-1) from BPND values, and tested the hypothesis that D 2 /D 3 receptor availability did not increase in patients from the first (off-leptin) to the second (on-leptin) scan (Figures 1b and c) . Z scores were calculated using the corresponding s.d. from control subjects, averaged and converted to one-tailed P values. The Z scores of the mean change score for patients were 0.81, 0.47, À0.75 and À1.33, respectively, in NAC, globus pallidus, putamen and caudate. All P values were non-significant ( > 0.2). Therefore, the null hypothesis (no increase) was accepted for all regions. We set 95% upper limits of 32, 10, 7 and 2% for the percentage BPND increase in the four regions. Figures 1b and c suggest, however, that changes in D 2 /D 3 receptor availability in the patients ranged from an increase after leptin replacement in the most ventral VOI (NAC) to a decrease in the most dorsal (caudate).
Using [ 3 H]spiperone in an autoradiographic study, Pfaffly et al. 2 observed that striatal basal D 2 /D 3 receptor availability did not differ between ob/ob and wild-type mice, but that leptin treatment for 8 days increased striatal D 2 /D 3 receptor availability in ob/ob mice, but decreased availability in wild-type mice. In a small sample of leptin-deficient humans, we observed no difference in BPNDs in comparison with a control group, and no significant increase from the 'off-leptin' to 'on-leptin' conditions.
Although brief leptin treatment decreased the weight of previously untreated ob/ob mice, they still weighed almost twice as much as wild-type mice. 2 In contrast, long-term leptin replacement had substantially normalized body weight and other endocrine functions of our patients. 9 Leptin replacement may have also normalized their central dopamine systems in ways, which persisted during the onemonth leptin-off period. Determination of whether D 2 /D 3 receptor availability and other dopamine system parameters are abnormal before the initiation of leptin replacement to individuals with this mutation awaits identification of new cases. 
